Coagulation parameters from all subjects from the AB002 phase 1 clinical study. Four cohorts were administered a single dose of AB002 (cohort 1, 0.5 µg/kg; cohort 2, 1.0 µg/kg; cohort 3, 2.0 µg/kg; cohort 4, 4.0 µg/kg [n = 4 each dose level]) or placebo (all placebo-dosed subjects are grouped together [n = 5]). Plasma samples were collected at specific intervals to observe the effect of drug administration on (A) aPTT, (B) APC-PCI complex formation, (C) prothrombin time (PT) and (D) protein C levels. For aPTT and PT, samples were analyzed at 0, 5, 15, 30 minutes, 1, 2, 24 hours, and 14 and 28 days. For APC-PCI, samples were analyzed at 0, 5, 15, 30 minutes, and 1, 2, 4, 24 hours, and, for protein C, samples were analyzed at 0, 1, 2, 4, and 24 hours. There were no measurable levels of APC-PCI complex in placebo-dosed subjects, thus data are not shown. Black dashed lines indicate laboratory reference ranges and red dashed lines indicate clinically significant ranges. All data are expressed as mean plus or minus SEM.